Takeda Pharmaceutical Co ADR (TAK) concluded trading on Thursday at a closing price of $15.39, with 3.03 million shares of worth about $46.57 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 12.01% during that period and on June 12, 2025 the price saw a gain of about 1.45%. Currently the company’s common shares owned by public are about 3.15B shares, out of which, 3.15B shares are available for trading.
Stock saw a price change of 2.67% in past 5 days and over the past one month there was a price change of 12.17%. Year-to-date (YTD), TAK shares are showing a performance of 16.24% which increased to 13.92% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $12.57 but also hit the highest price of $15.43 during that period. The average intraday trading volume for Takeda Pharmaceutical Co ADR shares is 2.10 million. The stock is currently trading 4.38% above its 20-day simple moving average (SMA20), while that difference is up 4.55% for SMA50 and it goes to 8.34% higher than SMA200.
Takeda Pharmaceutical Co ADR (NYSE: TAK) currently have 3.15B outstanding shares and institutions hold larger chunk of about 5.05% of that.
The stock has a current market capitalization of $48.44B and its 3Y-monthly beta is at 0.26. PE ratio of stock for trailing 12 months is 70.82, while it has posted earnings per share of $0.22 in the same period. Its PEG reads 1.49 and has Quick Ratio of 0.52 while making debt-to-equity ratio of 0.65. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TAK, volatility over the week remained 0.86% while standing at 0.77% over the month.
Stock’s fiscal year EPS is expected to rise by 131.00% while it is estimated to increase by 21.38% in next year. EPS is likely to grow at an annualized rate of 47.48% for next 5-years, compared to annual growth of 11.40% made by the stock over the past 5-years.
Coverage by BofA Securities stated Takeda Pharmaceutical Co ADR (TAK) stock as a Buy in their note to investors on March 16, 2023, suggesting a price target of $20 for the stock. Stock get a Neutral rating from JP Morgan on April 19, 2021.
